CATX Company Profile and Key Details

AMEX : CATX

Perspective Therapeutics

$3.00

-0.05-1.64%

At Close 4:00 PM

71.75

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Perspective Therapeutics, Inc. (CATX) stock declined over -1.64%, trading at $3.00 on AMEX, down from the previous close of $3.05. The stock opened at $3.02, fluctuating between $2.99 and $3.15 in the recent session.

Stock Snapshot

3.05

Prev. Close

231.75M

Market Cap

2.985

Day Low

-2.13

P/E Ratio

-1.41

EPS (TTM)

-0.1

Cash Flow per Share

3.02

Open

77.25M

Number of Shares

3.15

Day High

79.43%

Free Float in %

0.35

Book Value

1.25M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 23, 2026	3.02	3.15	2.99	3.00	1.25M
Jun 22, 2026	3.00	3.12	2.95	3.05	2.35M
Jun 18, 2026	3.02	3.13	2.93	2.95	7.66M
Jun 17, 2026	2.95	3.07	2.94	2.98	2.05M
Jun 16, 2026	2.97	3.00	2.91	2.93	765.1K
Jun 15, 2026	3.00	3.13	2.87	2.94	1.76M
Jun 12, 2026	2.94	3.02	2.94	2.95	1.03M
Jun 11, 2026	3.00	3.04	2.92	2.97	1.05M
Jun 10, 2026	2.98	3.06	2.91	2.95	1.14M
Jun 09, 2026	2.96	3.04	2.85	3.00	1.49M
Jun 08, 2026	3.10	3.13	2.90	2.93	1.26M
Jun 05, 2026	3.25	3.29	3.01	3.03	1.86M
Jun 04, 2026	3.55	3.63	3.16	3.25	3.62M
Jun 03, 2026	3.60	3.69	3.53	3.56	969.77K
Jun 01, 2026	3.91	4.06	3.65	3.66	1.45M
May 29, 2026	4.06	4.15	3.90	3.94	892.58K
May 28, 2026	4.14	4.24	4.02	4.05	1.25M
May 27, 2026	4.16	4.34	4.12	4.16	1.03M
May 26, 2026	4.03	4.22	3.93	4.16	1.52M
May 22, 2026	3.93	4.11	3.91	3.98	1.72M

Contact Details

Seattle, WA 99354

United States

https://www.perspectivetherapeutics.com 509 375 1202

About Company

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

Stock Peers

ELMD

-0.28-0.72%

Electromed, Inc.$38.40 MYO

-0.03-2.34%

Myomo, Inc.$1.25 VTAK

0.04+4.76%

Catheter Precision, Inc.$0.88 RMED

0.054+10.00%

Ra Medical Systems, Inc.$0.59 XTNT

-0.00459999-1.04%

Xtant Medical Holdings, Inc.$0.44 POAS

0.0295+9.18%

Phaos Technology Holdings (Caym$0.35 ASXC

0.0022+0.64%

Asensus Surgical, Inc.$0.35 PMI

0.0179+9.83%

Picard Medical, Inc.$0.20

Company Overview

Perspective Therapeutics, Inc. (AMEX:CATX) closed at $2.99 USD, losing -$0.06 (-1.97%) from the previous close of $3.05. The stock is currently mid-range between its 52-week high and low $1.96 and $6.16. With a market capitalization of about $230.98 million, Perspective Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.73). Key stats such as the average daily volume over the past year has been around 1.43 million shares, in line with its 52-week average. Headquartered in Seattle, WA, Perspective Therapeutics, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Johan Spoor, the company employs approximately 138 people and listed since November 10, 2005. Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices.

Technical Performance

CATX has shown mixed momentum, gaining 0.83% over the past week and -45.88% over the past quarter, though year-to-date performance is down -11.64%. Short-term trend indicators are bearishly aligned (SMA20 1.46%, SMA50 40.52%, SMA200 51.84%). The stock’s 14-day RSI is 58.16 (neutral), while the ATR of 0.51 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.86% below its high and over 216.25% above its low. Average 10-day trading volume of 2.92 million shares is significantly above the 3-month average of 1.47 million, indicating heightened recent market interest.

Valuation Metrics

Perspective Therapeutics, Inc. trades at a P/E ratio of -0.11, slightly below the S&P 500 average, with a price-to-sales ratio of 378.12 and a price-to-book ratio of 0.01 suggesting the stock is closer to book value. The P/FCF stands at -2.18, also above market averages.

Dividend & Fair Value

Perspective Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.39. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Perspective Therapeutics, Inc. generated EPS of -$1.46 over the past year. Five-year average earnings growth is -9.86%. Wall Street analysts project EPS growth of 1.01% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $8.00. The high target offers 490.16% upside. The low target suggests 162.3% downside. The mean target is $12.38. This offers 305.9% upside. Perspective Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by -13.79%. The prior quarter beat by 37.84%. Over the last six quarters, Apple has recorded several small beats. These include -3.85% in March 26, 2025.

Shareholding & Insider Activity

Perspective Therapeutics, Inc. has 74.26 million shares outstanding. The public float is 58.98 million shares, elevated short interest at 11.98% of float. This equals 6.29 million shares. The short ratio is 8.24 days. Institutional investors hold 72.34% of the float. Insiders own 18.82%. Lantheus Alpha Therapy, LLC holds 116.77 million shares, Morich Frank has 1.81 million shares and Streeter Jennifer has 1.72 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Perspective Therapeutics generated $10.80M in revenue, or $0.08 per share. Gross margin was 42.76%, operating margin -68.47%, and net profit margin -66.26%. Returns are negative, with ROA at -11.10% and ROE at -11.67%.
On valuation metrics, Perspective Therapeutics trades at a P/E of -0.11, P/S of 378.13 and P/B of 0.01. The current ratio is 8.75 and quick ratio is 8.75. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -3635.84 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -35.24.

Quarterly Financial Highlights

For the quarter ended Jun 30, 2022, Perspective Therapeutics posted revenue of $10.80M, down slightly from $10.05M in the prior quarter. Gross profit was $4.62M (margin 42.76%). Operating income was - $7.39M (margin -68.5%). Net income was- $7.15M (EPS - $0.05).
The company ended the quarter with $55.89M in cash and short-term investments, a total debt of $524.00K, and net debt of - $55.37M. Total assets were $64.44M, with equity of $61.28M. Financials further reflected weakness, with operating cash flow of - $2.84M, free cash flow of - $3.22M, and capital expenditures of - $381.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Perspective Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -20.66%, with price expected at $2.42 by July 06, 2026, within a range of $2.21 to $2.66 3-Month Outlook: Projected fall of -80.0%, reaching $0.61 by September 18, 2026, with a range of $0.42 to $0.74. 1-Year Outlook: Projected gain of 32.79%, with price at $4.05 by June 22, 2027, within a range of $0.00 to $4.56.

Key Takeaways

Perspective Therapeutics, Inc. (AMEX:CATX) shares are down -11.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Perspective Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.11. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $14.26, suggesting 367.54% upside. Our AI forecast model points to short-term weakness (-20.66% over two weeks), a medium-term fall (-80.0% over three months), and a longer-term gain (32.79% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Perspective Therapeutics, Inc. (CATX) stock price?

Perspective Therapeutics, Inc. (AMEX: CATX) stock price is $3.00 in the last trading session. During the trading session, CATX stock reached the peak price of $3.15 while $2.99 was the lowest point it dropped to. The percentage change in CATX stock occurred in the recent session was -1.64% while the dollar amount for the price change in CATX stock was - $0.05.

CATX's industry and sector of operation?

The AMEX listed CATX is part of Medical - Devices industry that operates in the broader Healthcare sector. Perspective Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CATX?

No Data

How CATX did perform over past 52-week?

CATX's closing price is 53.06% higher than its 52-week low of $1.96 where as its distance from 52-week high of $6.16 is -51.3%.

How many employees does CATX have?

Number of CATX employees currently stands at 138.

Link for CATX official website?

Official Website of CATX is: https://www.perspectivetherapeutics.com

How do I contact CATX?

CATX could be contacted at phone 509 375 1202 and can also be accessed through its website. CATX operates from 350 Hills Street, Seattle, WA 99354, United States.

How many shares of CATX are traded daily?

CATX stock volume for the day was 1.25M shares. The average number of CATX shares traded daily for last 3 months was 1.43M.

What is the market cap of CATX currently?

The market value of CATX currently stands at $231.75M with its latest stock price at $3.00 and 77.25M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	138
Beta	1.73
Sales or Revenue	$10.80M
5Y Sales Change%	-0.509%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Medical - Devices

CATX Company Profile and Key Details

Perspective Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Company Overview

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways